ADVANCING BREAST CARCINOMA CARE: THE EVOLVING ROLE OF ACCELERATED PARTIAL BREAST IRRADIATION

Abstract

Accelerated Partial Breast Irradiation (APBI) has emerged as a notable advancement in breast cancer management, offering a targeted radiation therapy approach that focuses on the specific region surrounding the tumor bed. This chapter delves into the understanding of APBI, discussing its techniques, benefits, and potential drawbacks. APBI, administered over a shorter duration than traditional whole breast irradiation, proves advantageous in terms of reduced treatment time and enhanced patient convenience. Indications
for APBI include early-stage breast cancer, particularly in patients with low to intermediate risk and those seeking a shorter
Treatment course due to age or health considerations.

However, the chapter also highlights potential drawbacks and controversies associated with APBI, such as limited long-term data on efficacy and safety, emphasizing the need for careful patient selection. Despite these considerations, APBI remains a promising approach for early-stage breast cancer, with ongoing research expected to refine its role in breast cancer management.

Authors

Dr. Vishwadeep Mishra
Assistant Professor
Department of Radiation Oncology
Rohilkhand Medical College and Hospital
Bareilly, Uttar Pradesh, India.

Dr. Sudeep Bisht
Assistant Professor
Department of Radiation Oncology
Rohilkhand Medical College and Hospital
Bareilly, Uttar Pradesh, India.

Dr. Rashmi Yadav
Senior Resident
Department of Radiation
Hind Institute of Medical Sciences
Barabanki, Uttar Pradesh, India.

I. INTRODUCTION

Breast cancer is one of the most prevalent malignancies affecting women worldwide. Over the years, advancements in diagnostic and therapeutic techniques have significantly improved the prognosis and quality of life for breast cancer patients. One such advancement that has gained attention is Accelerated Partial Breast Irradiation (APBI). APBI is a radiation therapy technique designed to target a specific region of the breast, rather than irradiating the entire breast. This chapter explores the role of APBI in breast cancer management, discussing its indications, techniques, benefits, and potential drawbacks.

II. UNDERSTANDING ACCELERATED PARTIAL BREAST IRRADIATION

APBI is a localized radiation therapy approach that delivers a higher dose of radiation to the area surrounding the tumor bed while sparing healthy breast tissue. This technique aims to achieve the same therapeutic effect as whole breast irradiation (WBI) but in a more focused and time-efficient manner. APBI is typically administered over a shorter treatment course, often lasting only five to ten days, compared to the standard six to seven weeks of WBI.[1]

III. INDICATIONS FOR APBI[3]

APBI is not suitable for all breast cancer patients, and careful patient selection is crucial. Its main indications include:

1. **Early-Stage Breast Cancer:** APBI is most commonly used for patients with early-stage breast cancer, typically Stage 0 to II. These patients have smaller tumors, clear margins, and no lymph node involvement[4].

2. **Low to Intermediate Risk:** Patients with low to intermediate-risk breast cancer are ideal candidates for APBI. They have a lower risk of recurrence and may benefit from the focused radiation therapy, reducing the potential side effects of WBI.

3. **Age and Health Status:** Age and overall health are also significant factors in considering APBI. Older patients or those with medical conditions that may make prolonged treatments difficult may opt for APBI for its shorter duration.

IV. TECHNIQUES OF APBI

1. **Intraoperative Radiation Therapy (IORT):** IORT involves delivering a single high dose of radiation to the tumor bed during surgery, immediately after tumor removal. This technique minimizes the exposure of surrounding healthy tissue to radiation.

2. **Brachytherapy:** Brachytherapy involves placing radioactive seeds or catheters directly into the tumor bed. It allows for precise delivery of radiation while sparing normal breast tissue[2,9,10].

3. **External Beam Radiation Therapy (EBRT):** EBRT involves delivering radiation from outside the body using a machine that precisely targets the tumor bed. Various EBRT

techniques can be used for APBI, including 3D conformal radiation therapy and intensity-modulated radiation therapy (IMRT)[5,6].

V. BENEFITS OF APBI

1. **Reduced Treatment Duration:** One of the most significant advantages of APBI is the shorter treatment duration compared to WBI. This can lead to improved patient convenience and compliance.

2. **Preserving Breast Appearance and Function:** By targeting a smaller area, APBI minimizes radiation exposure to healthy breast tissue. This can result in better cosmetic outcomes and reduced side effects, such as skin changes and breast shrinkage[8,11.]

3. **Quality of Life:** Patients receiving APBI often experience less fatigue and have a quicker recovery time, leading to a better quality of life during and after treatment[7,8,12].

VI. POTENTIAL DRAWBACKS AND CONTROVERSIES

1. **Limited Long-Term Data:** The long-term efficacy and safety of APBI are still being studied, and some experts argue that more data are needed to fully understand its impact on recurrence rates and late side effects.

2. **Patient Selection:** Selecting appropriate candidates for APBI is critical. Ineligible patients may experience higher rates of recurrence, highlighting the importance of careful patient selection.

VII. CONCLUSION

Accelerated Partial Breast Irradiation is a promising approach in the treatment of early-stage breast cancer. While it offers numerous benefits, including reduced treatment duration and improved quality of life, it should be carefully considered in the context of patient selection and the available treatment options. Future research will continue to shed light on the long-term outcomes and refine the role of APBI in breast cancer management.

REFERENCES

[1] Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001.
[2] Shah C, Vicini F, Shaitelman SF, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154-170.
[3] Polgár C, Van Limbergen E, Potter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94(3):264-273.
[4] Formenti, S. C., & Jozsef, G. (2012). Radiation therapy for early breast cancer after breast-conserving surgery. The New England Journal of Medicine, 366(22), 2110-2118.
[5] Livi, L., Meattini, I., Marrazzo, L., et al. (2015). Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. European Journal of Cancer, 51(4), 451-463.

[6] Olivotto, I. A., Whelan, T. J., Parpia, S., et al. (2013). Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. Journal of Clinical Oncology, 31(32), 4038-4045.

[7] Vaidya, J. S., Bulsara, M., Wenz, F., et al. (2014). Reduced mortality with partial-breast irradiation for early breast cancer: A meta-analysis of randomized trials. International Journal of Radiation Oncology, Biology, Physics, 90(3), 483-490.

[8] Vicini, F. A., Arthur, D. W., & Julian, T. B. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial. The Lancet, 394(10215), 2155-2164.

[9] Strnad, V., Ott, O. J., Hildebrandt, G., et al. (2020). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: A randomised, phase 3, non-inferiority trial. The Lancet, 395(10237), 366-374.

[10] Shah, C., Badiyan, S.,p Ben Wilkinson, J., et al. (2018). Treatment efficacy with accelerated partial breast irradiation (APBI): Final analysis of the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial. Annals of Surgical Oncology, 25(11), 3251-3258.

[11] Khan, A. J., Vicini, F. A., Beitsch, P., et al. (2012). Local control, toxicity, and cosmesis in women ≥70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. International Journal of Radiation Oncology, Biology, Physics, 84(2), 323-330.

[12] Whelan, T. J., Pignol, J. P., Julian, J. A., et al. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. The New England Journal of Medicine, 362(6), 513-520.

